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Abstract
Background: The healthcare expenditure on self-monitoring of blood glucose (SMBG) test strips under the
Nova Scotia Seniors' Pharmacare Program (NSSPP) has increased significantly in recent years. The objective of
this study was to identify the frequency and cost of claims for blood glucose monitoring test strips by NSSPP
beneficiaries in the fiscal year 2005/06 and to explore the variation in the use of test strips by type of treatment,
age and sex.
Methods:  Retrospective analysis was conducted using pharmacy administrative claims data for NSSPP
beneficiaries. Study subjects were aged ≥ 65 years on October 1, 2004, received SMBG test strips in the 110 days
prior to April 1, 2005, and were alive throughout the twelve month study period. Subjects were categorized into
four groups: insulin only, oral antihyperglycemic agents (OAA) only, both OAA and insulin; and no reimbursed
diabetes medications. Statistical analysis was performed to identify differences in expenditure by medication group
and in frequency of SMBG test strips claimed by medication group, age, and sex.
Results: Of 13,564 included beneficiaries, 13.2% were categorized as insulin only, 53.5% OAA only, 7.2% both
OAA and insulin, and 26.0% no reimbursed diabetes medications. Over half (58.7%) were femle. The insulin only
category had the highest mean (± SD) number of SMBG test strips claimed per day (2.0 ± 1.5) with a mean annual
total cost of $615 ± $441/beneficiary. Beneficiaries aged 80 years and above claimed fewer test strips than
beneficiaries below 80 years.
Conclusion: This population based study shows that in Nova Scotia the SMBG test strips claimed by the majority
of seniors were within Canadian guidelines. However, a small proportion of beneficiaries claimed for SMBG test
strips infrequently or too frequently, which suggests areas for improvement. The provincial drug plan covers the
majority of the costs of test strip utilization, suggesting that the majority of test strips claimed did not exceed the
maximum allowable cost (MAC) established in the program's MAC policy. Drug insurance programs need to work
with healthcare providers to determine if patients are using test strips optimally; and to determine their impact
on patient outcomes. In addition, they need to determine the cost-effectiveness of their SMBG test strip
reimbursement policies.
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Background
Diabetes mellitus is an important public health issue [1].
The increasing prevalence, extensive morbidity, and asso-
ciated high health care expenditures of diabetes pose an
increasing burden on affected individuals, the health care
system, and society as a whole [1]. Nova Scotia has one of
the highest prevalences of diabetes in Canada [2] as
approximately five percent of the population aged 20
years and above and fourteen percent of the population
aged 65 years and above have diabetes [3]. With the
increasing trend in diabetes prevalence, the total health-
care cost for individuals with diabetes in Canada is
expected to increase by 75 % from $4.7 billion in 2000 to
more than $8.1 billion in 2016[4]. The direct healthcare
cost associated with diabetes in Nova Scotia is projected to
increase from $175.5 million in 2005 to $249.3 million
in 2016 [4].
Diabetes testing supplies are integral to SMBG which con-
tributes substantial costs to the provincial health care
plans. The provincial government drug benefit programs
of Nova Scotia spent $2.66 million on insulin products,
$4.10 million on oral antihyperglycemic agents (OAA)
and $6.72 million on self-monitoring of blood glucose
(SMBG) test strips in the fiscal year 2004/05 [Personal
communication by Jianxiang Huang, M.D., Information
and Statistics Officer, Nova Scotia Department of Health
and Mike Joyce, BA., MBA, Senior Economic Advisor,
Pharmaceutical Services, Nova Scotia Department of
Health, March 19, 2008].
In the province of Nova Scotia, Canada, the Seniors' Phar-
macare program (NSSPP) is a publicly funded drug insur-
ance plan that reimburses drugs and medical supplies
listed in the Nova Scotia Formulary for eligible seniors in
the province. The beneficiaries of this program are Nova
Scotia residents with a minimum age of 65 years who
enroll by paying the required insurance premium and
who pay the required per prescription co-payment. The
NSSPP does not provide coverage for senior residents who
have private drug insurance, or coverage with another
public sector plan, e.g. with Veterans Affairs Canada or
with First Nations and Inuit Health. The beneficiary co-
payment during the study period was 33% of the total pre-
scription cost to a maximum of $30 with a minimum of
$3 per prescription. The annual maximum co-payment
was $360. Once beneficiaries reached a total annual co-
payment of $360, the plan covered 100% of eligible pre-
scription costs. Co-payment is calculated according to the
government fiscal year [5]. According to the NSSPP's cost
sharing policy, a maximum allowable cost (MAC) of
Canadian $0.74 was reimbursed for each test strip in the
fiscal year 2004/05. Patients who wish to use test strips
which cost more than the MAC, are required to pay the
difference [5]. This cost sharing policy is intended to both
reduce financial barriers to the practice of SMBG, while
encouraging cost-effective SMBG through beneficiary con-
tribution for the more expensive test strip brands.
Diabetes is associated with many complications, and
inappropriate management can increase the risk of cardi-
ovascular disorders, neurological disorders, foot sores and
wounds, retinopathy, and nephropathy. Reducing hyper-
glycemia has shown to be an important factor in the pre-
vention of diabetes-related complications [1]. Owing to
the complex manifestations associated with diabetes,
effective management of diabetes needs to be multifac-
eted with strategies which include: (1) educating patients
about the signs and symptoms of the disease and how to
assess their condition; (2) lifestyle interventions such as
regular physical activity, appropriate diet, weight manage-
ment, and reduced stress levels; and (3) medications
when required [6,7]. Currently two methods, SMBG and
laboratory monitoring of A1c are used to assess glycemic
control in patients with diabetes. SMBG shows a patient's
blood glucose levels at a particular time point whereas
A1c shows a patient's blood glucose control in the past
two or three months [8].
SMBG is considered to be a cornerstone of diabetes self-
management to monitor blood glucose levels and guide
patients in making adjustments to therapy or lifestyle to
achieve glycemic control [1,8-12]. SMBG helps in avoid-
ing episodes of high or low blood glucose levels among
patients [13]. SMBG also allows physicians to gather data
for appropriate clinical decision-making [14]. Qualitative
studies have revealed patients' views on the advantages
and disadvantages of SMBG. Patients report SMBG
enhances awareness of lifestyle modifications needing
adoption and raises the sense of success or failure to
achieve target blood glucose levels [10,15]. Patients have
also expressed the lack of interest shown by health profes-
sionals for the results of SMBG, compared to A1c levels,
which discouraged them to continue with SMBG. This
highlights the crucial role played by health professionals
in educating patients on how to respond to testing results
and in continuously reinforcing this information [10,15].
Furthermore, the frequency of SMBG has been found to
vary among patients with diabetes in different jurisdic-
tions [16-20]. An observational study evaluating insur-
ance coverage policies for blood glucose devices and
testing supplies found an increased rate of testing among
patients once blood glucose monitors were provided free
[21], while a randomized controlled trial (RCT) found no
effect in 6-month glycosylated hemoglobin (A1c)
between patients with Type 2 diabetes receiving free
SMBG test strips and control subjects [22]. Patients with
type 1 diabetes performing three or more self tests per day
showed statistically and clinically significant associationBMC Health Services Research 2008, 8:111 http://www.biomedcentral.com/1472-6963/8/111
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with A1c levels [23]. However the optimal frequency of
SMBG per day is uncertain in patients with type 2 diabetes
who are recommended to follow lifestyle interventions
alone or in combination with OAAs [8,23-26].
Clinical practice guidelines recommend SMBG to both
insulin and non insulin treated diabetes patients. The
Canadian clinical practice guideline issued by the Cana-
dian Diabetes Association in the year 2003 with a recom-
mendation to test three or more times a day in patients
receiving insulin and at least once a day in patients receiv-
ing oral antihyperglycemic agents [27]. These guidelines
were synthesized by experts using standard criteria to
assign levels of evidence from published studies.
The role of SMBG in patients with diabetes is widely
debated [24,25,28]. Previous studies have proven the ben-
eficial effect of SMBG in patients with type 1 diabetes
[1,23] and in patients with type 2 diabetes who use insu-
lin [8,23]. Patients with type 2 diabetes, who do not use
insulin, but self monitor blood glucose, have not shown
significant reduction in A1c levels in many prospective
studies and randomized controlled trials [22,24,25,29-
33] and a small effect of 0.39% decrease in A1c levels
compared to control in one systematic review [30]. Stud-
ies assessing the effect of SMBG in non insulin treated
patients have methodological issues, heterogeneity of the
study population and variations in the interventions
offered [34,35]. These studies lack homogeneity and the
ability to measure the true impact of SMBG in non insulin
treated patients [34,35]. Some experts support regular
SMBG while others suggest that in non insulin treated
patients, there is a need to weigh benefits with healthcare
expenditures before advocating routine practice [34,35].
Objective
The purpose of this population based study was to assess
the utilization of SMBG test strips within a Canadian pro-
vincial drug plan which incorporates both a copayment
and a policy of paying up to a maximum amount per test
strip. We were interested in the pattern of test strips
claimed by both insulin and non insulin treated patients
and the extent of their adherence to guidelines for SMBG.
The specific objectives of this study were (1) to analyze the
frequency of SMBG test strips claimed by the beneficiaries
of NSSPP based on treatment category, sex and age group;
and (2) to estimate the government and beneficiary
expenditure on SMBG test strips in the NSSPP, which has
both a beneficiary copayment and a policy of paying up to
a maximum amount per test strip.
Methods
Study Design
A retrospective database analysis was conducted using
administrative pharmacy claims data to measure the fre-
quency of SMBG test strips claimed, and healthcare
expenditure on test strips.
Study Population
The NSSPP program had 115,959 total beneficiaries in the
fiscal year 2005/06. The NSSPP had 13,564 beneficiaries
aged ≥ 65 years on October 1, 2004 who had received
SMBG test strips in the 110 days prior to April 1, 2005 or
at any time during the fiscal year 2005/06 and were eligi-
ble for Pharmacare for the entire period from October 1,
2004 to March 31, 2006. The 110 days time frame was
chosen because the maximum days supply for each pre-
scription in the NSSPP is 100 days.
Diabetes medications and SMBG test strips dispensed to
beneficiaries were determined for the period October 1,
2004 to April 1, 2005 using World Health Organization's
Anatomical Therapeutic Classification (ATC) [36] and
Product Identification Number (PIN) assigned by the
Pharmacy Association of Nova Scotia's (PANS) OPIN-
IONS program [37]. Beneficiaries were classified into four
groups depending on their pharmacy claims history:
1. Insulin products only,
2. OAA only,
3. Both insulin products and OAA,
4. No reimbursed diabetes medications.
The study population was stratified by sex (male, female)
and age groups (65–69, 70–74, 75–79 and 80+ years) to
assess variation in test strips claimed across these groups
based on treatment. All the SMBG test strips dispensed to
beneficiaries between April 1, 2005 and March 31, 2006
were included. The numbers of SMBG test strips dis-
pensed were identified by PIN [37] from the pharmacy
administrative claims data.
Data Sources
Pharmacy administrative claims data were accessed
through the Population Health Research Unit (PHRU),
Dalhousie University [38]. To ensure confidentiality,
patient records in the NSSPP database have unique
encrypted patient identifiers according to Canadian Insti-
tute for Health Information (CIHI) encryption standards
[38]. Pharmacy administrative claims data on SMBG test
strips for the fiscal year 2004/05 and 2005/06 were exam-
ined. All data were provided to researchers at the individ-
ual patient level via a secure computing system. The
Health Sciences Human Research Ethics Board, Dalhousie
University, Halifax, Nova Scotia, approved this study.BMC Health Services Research 2008, 8:111 http://www.biomedcentral.com/1472-6963/8/111
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Data Analysis
The frequency of SMBG test strips claimed by NSSPP ben-
eficiaries with diabetes in the fiscal year 2005/06 was esti-
mated from the pharmacy claims data using descriptive
statistics stratified by treatment group, sex, and age group.
Univariate between-group comparisons were carried out
to understand the relationship of age and sex with SMBG
test strips claimed in the four treatment groups. The data
had a skewed distribution hence the nonparametric
Kruskal-Wallis test was used for between-group compari-
sons. The statistical significance level was set a priori at α =
0.05. The data analysis was conducted using SAS 9.1.3
[39]. Data are reported as mean ± standard deviation.
Healthcare expenditure on SMBG test strips claimed by
beneficiaries in the fiscal year 2005/06 was estimated
from the pharmacy claims. Between-groups comparisons
were carried out using the same methods as the frequency
analysis above. All results were reported in Canadian dol-
lars.
Results
Characteristics of beneficiaries receiving SMBG test strips
13,564 beneficiaries of NSSPP were included in the study.
More than one half of the beneficiaries were females
(58.7%). The mean age of the beneficiaries was 74.9 years
(standard deviation [SD]:6.7 years). There were 13.2% of
beneficiaries identified to be receiving insulin products,
53.5% receiving OAA, 7.4 % receiving both insulin prod-
ucts and OAA, and the remaining 25.9 % had no claims
for diabetes medications.
SMBG test strips claimed by NSSPP beneficiaries
Table 1 shows the number of beneficiaries and mean
number of SMBG test strips claimed per day per benefici-
ary by treatment group. Patients receiving insulin only or
insulin with OAA claimed a mean [SD] of 2.0 [1.5] or 2.0
[1.3] test strips per day. Those taking OAAs without insu-
lin claimed a mean [SD] of 1.0 [0.9] test strips per day,
while those taking no diabetes medications claimed a
mean [SD] of 0.7 [0.6] test strips per day. This variation by
treatment group was statistically significant by the
Kruskall-Wallis test (p < 0.001).
There was no statistically significant variation in the
number of test strips claimed by sex (p = 0.13). The varia-
tions by treatment category and by age were statistically
significant (p < 0.001 and p < 0.02 respectively). The dis-
tribution of the numbers of SMBG test strips claimed by
beneficiaries was highly (positively) skewed. Evidence of
this is seen in Table 2.
Healthcare expenditure on SMBG test strips
NSSPP covered 91.5%, 87.2%, 92.2%, and 83.2% of the
total cost for beneficiaries receiving insulin products only,
OAA only, insulin products and OAA, and no reimbursed
diabetes medications respectively. Table 1 shows the
mean annual cost of SMBG test strips per beneficiary by
treatment category.
The major proportion of the healthcare expenditure on
SMBG test strips is covered by the government through
the NSSPP because the MAC on test strips covers a signif-
icant proportion of the actual price of a number of brands
of test strips. Also a large proportion of the beneficiaries
likely reached their maximum annual copayment during
the study period with the program subsequently paying
the total amount. The difference in total cost by treatment
category was statistically significant (p < 0.001). The use
of private or third party insurance by the beneficiaries to
cover their share was not known.
Discussion
SMBG test strips claimed by beneficiaries
This population-based study provides an insight into the
patterns of SMBG test strips claimed by the beneficiaries
Table 1: Blood glucose monitoring test strips claimed and costs by treatment category, NSSPP for 2005/06
Treatment Category N (%) Number of 
Beneficiaries
Mean (SD) SMBG 
Test Strips Claimed*
Mean (SD) 
Government 
Contribution Through 
the NSSPP+ (Can $)
Mean (SD) Beneficiary 
Contribution Through 
Copayment and MAC 
policy+ (Can $)
Mean (SD) Total 
Cost+ (Can$)
Insulin products only 1786 (13.2) 2.0 (1.5) 562.17 (414.52) 52.34 (43.58) 614.50 (441.31)
Oral 
antihyperglycemic 
agents only
7252 (53.5) 1.0 (0.9) 271.61 (241.59) 39.90 (38.18) 311.51 (262.97)
Insulin products + 
Oral 
antihyperglycemic 
agents
1006 (7.4) 2.0 (1.3) 546.94 (361.59) 46.26 (38.90) 593.20 (382.50)
No reimbursed 
diabetes medications
3520 (25.9) 0.7 (0.6) 182.13 (177.88) 36.75 (34.84) 218.89 (197.77)
*Results per day
+Annual costs per beneficiaryBMC Health Services Research 2008, 8:111 http://www.biomedcentral.com/1472-6963/8/111
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of NSSPP in the fiscal year 2005/06. SMBG test strips
claimed was used to identify the frequency of SMBG by
the beneficiaries as in other studies [21]. However test
strips claimed in our population by beneficiaries receiving
OAA (about 30/month) greatly exceeded that in the study
of diabetes patients using sulfonylureas in a United States
(US) Health Maintenance Organization (approximately
10 test strips were used per month) [21]. The US study was
conducted in 1995 when different clinical practice guide-
lines were in place [21]. In addition, Nova Scotia has a
provincial diabetes care program with 39 centers across
the province educating patients about the role of SMBG
[40]. A study of the claims for SMBG test strips in the Drug
Plan in Saskatchewan, Canada in 2001 noted that for
patients with type 1 diabetes, the average patient's share of
the cost was 50.9% compared to 8.5% in our study [12].
According to the Canadian Diabetes Association 2003
Clinical Practice Guidelines for the Prevention and Man-
agement of Diabetes in Canada, the optimal SMBG fre-
quency for type 1 patients is three or more tests per day
and at least one test a day for patients with type 2 diabetes
[27]. In this study, the average daily SMBG test strips
claimed for four treatment categories was: [1] 2 for insulin
only; [2] 1 for OAA only; [3] 2 for insulin and OAA; and,
[4] less than 1 for no reimbursed diabetes medications.
The results suggest insulin users claim more test strips
than non insulin users with the highest mean value for
beneficiaries receiving only insulin therapy. These results
suggest that current utilization in this population is in
accordance with the Canadian clinical practice guidelines
for patients receiving insulin alone or in combination
with OAA [27]. There is lack of firm evidence to support
daily self-monitoring for patients receiving only OAA
[8,22-26,28,29]. Similarly there is limited evidence to
support self-monitoring in those beneficiaries (>3000)
who had no claims for antidiabetic medications. The
lower frequency of in SMBG test strips claimed by benefi-
ciaries aged ≥ 80 years was similar to previous studies
which have found a decline in self-monitoring with
increased age [20,41].
Table 2 shows a significant variation in SMBG test strips
claimed by the beneficiaries in the fiscal year 2005/06.
The highest and the lowest quartile results indicate
extreme deviation from clinical practice guidelines. The
lower and upper quartile values clearly suggest lack of
concordance between SMBG by the beneficiaries and the
clinical practice guidelines which recommend ≥ 3 self-
tests per day for type 1 diabetes and at least one self-test
daily for type 2 diabetes treated with medications [27].
Beneficiaries in the no reimbursed diabetes medications
category may have received products not captured in the
Pharmacare claims system. This may be confirmed by rec-
ognizing that:
(1) Beneficiaries might have been receiving insulin or an
OAA not covered by NSSPP such as insulin glargine (Lan-
tus®) or determir (Levimer®) ; chlorpropamide (Diab-
inese®); glimipiride (Amaryl®); repaglinide
(GlucoNorm®); nateglinide (Starlix®) [42]. Hence they
paid out of pocket for these products or their physicians
might have given them samples provided by pharmaceu-
tical representatives. A client sample (n = 1342) from a
regional Nova Scotia diabetes care centre for the 12
month period of January 1, 2006 – December 31, 2006
included 501 seniors (37.4%). Of these 501 seniors, only
16 (3.2%) were taking one of the medications not reim-
bursed by Pharmacare [Personal communication by
Zlatko Karlovic, B.E., Data Manager, Diabetes Care Pro-
gram of Nova Scotia and Peggy Dunbar, MEd, PDt, CDE,
Coordinator, Diabetes Care Program of Nova Scotia,
March 31, 2008].
(2) Certain insulin and OAA products are covered under
exception status for the NSSPP and beneficiaries must
meet specific criteria to be eligible for coverage by NSSPP.
Products for which coverage is contingent on meeting
exception criteria include insulin lispro (Humalog®); insu-
lin aspart (NovoRapid®); metformin/rosiglitazone (Avan-
damet®); rosiglitazone (Avandia®); pioglitazone (Actos®)
[42].
(3) Some beneficiaries receive insulin injections from out-
patient clinics which supply the medications and there-
fore no claims are made to the NSSPP.
(4) Beneficiaries may not initially fill a prescription for a
diabetes medication until they determine whether they
can stabilize their diabetes with diet and lifestyle modifi-
cations. A proportion of these beneficiaries may go on to
Table 2: Blood glucose monitoring test strips claimed per day by treatment category, NSSPP for 2005/06
Treatment Category Quartile 1 (Q1) Quartile 2 (Q2) Quartile 3 (Q3) Quartile 4 (Q4)
Insulin products only 0.8 1.7 2.7 12.7
Oral antihyperglycemic agents only 0.3 0.8 1.4 9.9
Insulin products + Oral antihyperglycemic agents 1.1 1.6 2.7 8.5
No reimbursed diabetes medications 0.3 0.5 0.8 6.6BMC Health Services Research 2008, 8:111 http://www.biomedcentral.com/1472-6963/8/111
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fill a prescription for a diabetes medication many months
after they start using SMBG test strips. However, a report
examining a sample of patients registered in the Diabetes
Care Program of Nova Scotia over age 19 in the calendar
year 2006 indicated that of 6258 patients with type 2 dia-
betes, 1505 (24%) were managed by diet alone and 1137
(75.5%) of these patients reported SMBG. [Personal com-
munication by Peggy Dunbar, MEd, PDt, CDE, Coordina-
tor, Diabetes Care Program of Nova Scotia, January 16,
2008]
Healthcare expenditure on SMBG test strips
This study highlights the healthcare expenditure on test
strips for the fiscal year 2005/06 for NSSPP beneficiaries.
The cost varied significantly among four treatment groups
and was considerably higher for beneficiaries using insu-
lin. The mean total cost of test strips per beneficiary was
highest for beneficiaries only on insulin therapy. These
results are similar to those reported in previous studies
[12,43]. Despite the NSSPP's beneficiary copayment and
its policy of paying only up to a maximum amount per
test strip, the government covers the majority of the cost
for test strips and a small portion is managed by the ben-
eficiaries as shown in Table 1.
The increased claims and the associated costs of SMBG test
strips for beneficiaries receiving insulin could be due to
increased risk of hypoglycemia arising from insulin use
and use of results to regulate insulin regimen [43]. Appro-
priate management of hypoglycemia through self testing
has shown benefit in patients with type 1 diabetes
[27,44]. However, evidence supporting the benefit of test-
ing remains uncertain in non insulin treated patients
[8,22,25,29,31]. In this study, the healthcare expenditure
on self-monitoring by non insulin treated beneficiaries is
significant for both the drug insurance plan and the indi-
vidual beneficiary with lack of firm evidence supporting
impact on long term outcomes and the cost effectiveness
of such practice [22,35,45].
Limitations
This study provides insight into use of SMBG test strips in
a provincial pharmacare program of 115, 959 senior ben-
eficiaries which covers 32 different brands of test strips.
Limitations to the study include: (1) test strips claimed by
beneficiaries may not all have been used and we were una-
ble to measure actual use and appropriateness of tech-
nique. (2) Test strips used by beneficiaries in hospitals
were not determined. (3) Beneficiaries who have diabetes
but do not practice SMBG and who did not receive test
strips in the study period are not included. Beneficiaries
who did not receive test strips for the entire study period
might influence the study findings. (4) Changes in disease
severity of beneficiaries during the study period who were
later put on diabetes medications and practiced SMBG
have not been included in the study. (5) We did not have
actual diagnosis (type 1 or type 2) and a small number of
beneficiaries receiving only insulin may have type 2 dia-
betes. (6) A small percentage of beneficiaries who receive
insulin (such as Lantus®) or OAA agents (certain thiazo-
linediones or sulfonylurea derivatives) which are not
reimbursed by the NSSPP may have been assigned to an
incorrect treatment group [42]. (7) The NSSPP does not
cover citizens over 65 years of age who have drug coverage
through a federal or private insurance program and those
over 65 years who chose not to pay the Nova Scotia Sen-
iors' Pharmacare premium; hence they were excluded in
this study. (8) It is not known whether the beneficiaries
made private insurance claims to cover their share of the
cost.
Conclusion
This population based study shows in the Canadian prov-
ince of Nova Scotia, the SMBG test strips claimed for the
majority of the senior beneficiaries were found to be
within Canadian guideline recommendations. However,
the results show that a small proportion of beneficiaries
who claimed for SMBG test strips infrequently or too fre-
quently which suggests areas for improvement. The pro-
vincial drug plan covers the majority of the costs of test
strips utilization, suggesting the majority of test strips
claimed do not exceed the maximum allowable cost
(MAC) established in the program's MAC policy [5]. Drug
insurance programs need to work with health care provid-
ers to determine if patients are using test strips optimally;
and to determine their impact on patient outcomes. In
addition, they need to determine the cost effectiveness of
their SMBG test strip reimbursement policies.
Abbreviations
A1c: Glycosylated hemoglobin, ATC: Anatomical Thera-
peutic Classification, CIHI: Canadian Institute for Health
Information, MAC: Maximum allowable cost, NSSPP:
Nova Scotia Seniors' Pharmacare Program, OAA: Oral
Antihyperglycemic Agents, PHRU: Population Health
Research Unit, PIN: Product Identification Number, RCT:
Randomized control trial, SD: Standard deviation, SMBG:
Self-monitoring of blood glucose.
Competing interests
Charmaine Cooke and Chiranjeev Sanyal received salary
support from an unconditional grant from the Nova Sco-
tia Department of Health to Dalhousie University. Dr.
Ingrid Sketris has received a grant from the Nova Scotia
Department of Health.
Authors' contributions
CS was involved with study design, data analysis, dissem-
inating results and preparing the manuscript. SDGBMC Health Services Research 2008, 8:111 http://www.biomedcentral.com/1472-6963/8/111
Page 7 of 8
(page number not for citation purposes)
designed the study, planned the analysis, coordinated the
project and critically revised the manuscript. CC was
involved with study design, coordinating the project and
critically revising the manuscript. IS participated in the
design of the study, coordinated the project and critically
revised the manuscript. DMF conceived the project and
brought in policy perspectives to the project. GF contrib-
uted statistical expertise and critically revised the manu-
script. All authors have read and approved the final
version.
Acknowledgements
Ingrid Sketris holds a research chair in drug use management and policy 
funded by Canadian Health Services Research Foundation/Canadian Insti-
tutes of Health Research/Nova Scotia Health Research Foundation. Chiran-
jeev Sanyal was provided salary support under this chair and also from Drug 
Evaluation Alliance of Nova Scotia (DEANS), Nova Scotia Department of 
Health.
Nova Scotia Department of Health, through the DEANS, for providing 
funding to access the data from Population Health Research Unit, Dalhousie 
University.
Jill Casey, Senior Research Analyst, Population Health Research Unit, Dal-
housie University, for technical assistance.
Ethel Langille Ingram and Jocelyn LeClerc for their assistance.
The observations and opinions are those of the investigators and do not 
represent the opinions of the Nova Scotia Department of Health, Canadian 
Health Services Research Foundation, Canadian Institutes of Health 
Research or Nova Scotia Health Research Foundation.
References
1. Consensus statement on self-monitoring in diabetes: Insti-
tute of health economics, Alberta, Canada, November 14–
16, 2006.  International Journal of Technology Assessment in Health Care
2007, 23(01):146-151.
2. Prevalence of diabetes in Canada by province, and sex for
persons 20 years and older (excluding New Brunswick, New-
foundland, Nunavut, Northwest Territories)   [ h t t p : / /
secure.cihi.ca/cihiweb/en/pirc_indicators_7d_Province_sex_e.html].
Accessed on July 19, 2007
3. Diabetes in Nova Scotia. A ten year perspective by: Diabetes
care program of Nova Scotia   [http://www.diabetescarepro
gram.ns.ca/statistics/diab.pdf]. Accessed on July 19, 2007
4. Ohinmaa Arto, Jacobs Philip, Simpson Scot, Johnson Jeffrey A: The
projection of prevalence and c o s t  o f  d i a b e t e s  i n  C a n a d a :
2000 to 2016.  Can J Diabetes 2004, 28:116-123.
5. Questions and Answers about Pharmacare Benefits and
Reimbursement   [http://www.gov.ns.ca/health/Pharmacare/bene
fitsfaq.asp]. Accessed on January 8, 2008
6. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O:
Multifactorial intervention and cardiovascular disease in
patients with type 2 diabetes.  N Engl J Med 2003, 348:383-393.
7. Goede P, Lund-Andersen H, Parving HH, Pedersen O: Effect of a
multifactorial intervention on mortality in type 2 diabetes.  N
Engl J Med 2008, 358:580-591.
8. Saudek CD, Derr RL, Kalyani RR: Assessing glycemia in diabetes
using self-monitoring blood glucose and hemoglobin A1c.
JAMA 2006, 295:1688-1697.
9. Mensing C, Boucher J, Cypress M, Weinger K, Mulcahy K, Barta P,
Hosey G, Kopher W, Lasichak A, Lamb B, Mangan M, Norman J, Tanja
J, Yauk L, Wisdom K, Adams C: National standards for diabetes
self-management education.  Diabetes Care 2006, 29(Suppl
1):S78-85.
10. Peel E, Parry O, Douglas M, Lawton J: Blood glucose self-monitor-
ing in non-insulin-treated type 2 diabetes: A qualitative study
of patients' perspectives.  Br J Gen Pract 2004, 54:183-188.
11. Stewart D, McCaig D, Davie A, Juroszek L, Blackwood L, Findlay N,
McCarthy S: Glucose self-monitoring in primary care: A sur-
vey of current practice.  J Clin Pharm Ther 2004, 29:273-277.
12. Johnson JA, Pohar SL, Secnik K, Yurgin N, Hirji Z: Utilization of dia-
betes medication and cost of testing supplies in Saskatch-
ewan, 2001.  BMC Health Serv Res 2006, 6:159.
13. American diabetes association. Checking your blood glucose
[http://www.diabetes.org/type-2-diabetes/blood-glucose-checks.jsp].
Accessed on July 19, 2007
14. Tieszen KL, New JP: Alternate site blood glucose testing: Do
patients prefer it?  Diabet Med 2003, 20:325-328.
15. Peel E, Douglas M, Lawton J: Self monitoring of blood glucose in
type 2 diabetes: Longitudinal qualitative study of patients'
perspectives.  BMJ 2007, 335:493.
16. Evans JM, Newton RW, Ruta DA, MacDonald TM, Stevenson RJ, Mor-
ris AD: Frequency of blood glucose monitoring in relation to
glycaemic control: Observational study with diabetes data-
base.  BMJ 1999, 319:83-86.
17. Hjelm Katarina, Nyberg Per, Apelqvist Jan: Self-monitoring of
blood glucose; frequency, determinants and self-adjustment
of treatment in an adult Swedish diabetic population utilisa-
tion and determinants of SMBG.  Practical Diabetes Int 2001,
18(5):157-163.
18. Karter AJ, Ferrara A, Darbinian JA, Ackerson LM, Selby JV: Self-
monitoring of blood glucose: Language and financial barriers
in a managed care population with diabetes.  Diabetes Care
2000, 23:477-483.
19. Karter AJ, Stevens MR, Herman WH, Ettner S, Marrero DG, Safford
MM, Engelgau MM, Curb JD, Brown AF, Translating Research Into
Action for Diabetes Study Group: Out-of-pocket costs and diabe-
tes preventive services: The translating research into action
for diabetes (TRIAD) study.  Diabetes Care 2003, 26:2294-2299.
20. Harris MI, Cowie CC, Howie LJ: Self-monitoring of blood glu-
cose by adults with diabetes in the United States population.
Diabetes Care 1993, 16:1116-1123.
21. Soumerai SB, Mah C, Zhang F, Adams A, Barton M, Fajtova V, Ross-
Degnan D: Effects of health maintenance organization cover-
age of self-monitoring devices on diabetes self-care and glyc-
emic control.  Arch Intern Med 2004, 164:645-652.
22. Johnson JA, Majumdar SR, Bowker SL, Toth EL, Edwards A: Self-
monitoring in type 2 diabetes: A randomized trial of reim-
bursement policy.  Diabet Med 2006, 23:1247-1251.
23. Karter AJ, Ackerson LM, Darbinian JA, D'Agostino RB Jr, Ferrara A,
Liu J, Selby JV: Self-monitoring of blood glucose levels and gly-
cemic control: The Northern California Kaiser Permanente
diabetes registry.  Am J Med 2001, 111:1-9.
24. Coster S, Gulliford MC, Seed PT, Powrie JK, Swaminathan R: Self-
monitoring in type 2 diabetes mellitus: A meta-analysis.  Dia-
bet Med 2000, 17:755-761.
25. Faas A, Schellevis FG, Van Eijk JT: The efficacy of self-monitoring
of blood glucose in NIDDM subjects. A criteria-based litera-
ture review.  Diabetes Care 1997, 20:1482-1486.
26. Harris MI, National Health and Nutrition Examination Survey
(NHANES III): Frequency of blood glucose monitoring in rela-
tion to glycemic control in patients with type 2 diabetes.  Dia-
betes Care 2001, 24:979-982.
27. Canadian Diabetes Association Clinical Practice Guidelines Expert
Committee:  Canadian Diabetes Association 2003 Clinical
Practice Guidelines for the Prevention and Management of
Diabetes in Canada.  Can J Diabetes 2003, 27(Suppl 2):S1-152.
28. Coster S, Gulliford MC, Seed PT, Powrie JK, Swaminathan R: Moni-
toring blood glucose control in diabetes mellitus: A system-
atic review.  Health Technol Assess 2000, 4:i-iv. 1–93
29. Farmer A, Wade A, Goyder E, Yudkin P, French D, Craven A, Holman
R, Kinmonth AL, Neil A: Impact of self monitoring of blood glu-
cose in the management of patients with non-insulin treated
diabetes: Open parallel group randomised trial.  BMJ 2007,
335:132.
30. Welschen LM, Bloemendal E, Nijpels G, Dekker JM, Heine RJ, Stalman
WA, Bouter LM: Self-monitoring of blood glucose in patients
with type 2 diabetes who are not using insulin.  Cochrane Data-
base Syst Rev 2005:CD005060.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Health Services Research 2008, 8:111 http://www.biomedcentral.com/1472-6963/8/111
Page 8 of 8
(page number not for citation purposes)
31. Holmes V, Griffiths P: Self-monitoring of glucose levels for peo-
ple with type 2 diabetes.  Br J Community Nurs 2002, 7:41-46.
32. Tengblad A, Grodzinsky E, Lindstrom K, Molstad S, Borgquist L, Ost-
gren CJ: Self-monitoring of blood glucose and glycaemic con-
trol in type 2 diabetes.  Scand J Prim Health Care 2007, 25:140-146.
33. Davis WA, Bruce DG, Davis TM: Is self-monitoring of blood glu-
cose appropriate for all type 2 diabetic patients? The Fre-
mantle diabetes study.  Diabetes Care 2006, 29:1764-1770.
34. Ipp E, Aquino RL, Christenson P: Point: Self-monitoring of blood
glucose in type 2 diabetic patients not receiving insulin: The
sanguine approach.  Diabetes Care 2005, 28:1528-1530.
35. Davidson MB: Counterpoint: Self-monitoring of blood glucose
in type 2 diabetic patients not receiving insulin: A waste of
money.  Diabetes Care 2005, 28:1531-1533.
36. About the ATC/DDD system   [http://www.whocc.no/atcddd/].
Accessed on July 19, 2007
37. OPINIONS database   [http://pans.ns.ca/
default.asp?id=190&sfield=content.id&search=6&mn=5.23]. Accessed
on January 17, 2008
38. Population health research unit   [http://www.phru.dal.ca].
Accessed on July 19, 2007
39. SAS institute, inc   [http://www.sas.com/]. Accessed on July 19,
2007
40. Diabetes care program of Nova Scotia   [http://www.diabetes
careprogram.ns.ca]. Accessed on January 16, 2008
41. Bode BW, Gross TM, Thornton KR, Mastrototaro JJ: Continuous
glucose monitoring used to adjust diabetes therapy
improves glycosylated hemoglobin: A pilot study.  Diabetes Res
Clin Pract 1999, 46:183-190.
42. The Nova Scotia formulary – January 2007   [http://
www.gov.ns.ca/health/Pharmacare/formulary.pdf]. Accessed on June
02, 2008
43. Mitchell CG, Simpson SH, Johnson JA: The cost of diabetes testing
strips in Saskatchewan, 1996: A retrospective database anal-
ysis.  Canadian Journal of Diabetes 2003, 27(2):149-153.
44. Goldstein DE, Little RR, Lorenz RA, Malone JI, Nathan DM, Peterson
CM, American Diabetes Association: Tests of glycemia in diabe-
tes.  Diabetes Care 2003, 26(Suppl 1):S106-8.
45. Neeser K, Erny-Albrecht K, Weber C: Cost-effectiveness of self-
monitoring of blood glucose in type 2 diabetic patients not
receiving insulin.  Diabetes Care 2006, 29:480;. author reply 480-1
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1472-6963/8/111/pre
pub